The efficacy and toxicity of neoadjuvant chemotherapy (NAC) with mitomycin-C, vincristine and cisplatin (MVC) were assessed in bulky cervical carcinoma patients.
Forty-six patients with stage IB2 to IIB cervical cancer were treated with intravenous combination of mitomycin-C 10 mg/m2, vincristine 1 mg/m2 and cisplatin 75 mg/m2 every 3 weeks. After three cycles of NAC, the patients either underwent surgery or radiation therapy, depending on their suitability for radical hysterectomy.
All 46 patients enrolled in this study were suitable for surgery after NAC. Twenty (44%) patients had risk factors after surgery and received postoperative radiation. Toxic nonhematologic reactions consisted primarily of grades 1–2 nausea and vomiting (87%) and the most common hematologic toxicity was anemia (60%). Clinical responses occurred in 83% (38/46) of patients, including 24% (11/46) with a complete response (CR) and 13% (6/46) with a pathologically determined complete response. For a median follow up period of 28 months, the 3-year disease-free and overall survival rates were 74% and 80%, respectively. Pathologically confirmed lymph node metastasis or parametrial involvement and an initial tumor size ≥4 cm were associated with shorter disease-free survival (P=0.040, P=0.000, P=0.025, respectively).
Intravenous administration of MVC as a NAC seems to be well tolerated and beneficial in patients with stage IB2 to IIB cervical cancer.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer. 1993; 54: 594-606
- Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma.Obstet. Gynecol. 1975; 46: 507-510
- Prognostic significance of the depth of invasion relating to nodal metastases, parametrial extension, and cell types. A study of 628 cases with Stage IB, IIA, and IIB cervical carcinoma.Cancer. 1984; 54: 3035-3042
- Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix.Gynecol. Oncol. 1993; 49: 156-165
- Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy.N. Engl. J. Med. 1999; 340: 1198-1200
- Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study.Obstet. Gynecol. 1988; 71: 344-348
- Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor.Gynecol. Oncol. 1989; 33: 225-230
- Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer.Br. J. Obstet. Gynaecol. 1987; 94: 583-588
- The integration of chemotherapy into the management of locally advanced cervical cancer: a pilot study.Gynecol. Oncol. 1984; 19: 1-7
- Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial.Acta. Oncol. 1995; 34: 257-259
- Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.J. Clin. Oncol. 1999; 17: 756-760
- Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.Gynecol. Oncol. 1997; 65: 348-356
- Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.Eur. J. Cancer. 2003; 39: 2470-2486
- Adjuvant chemotherapy after radical hysterectomy for cervical cancer.Bailliere's Clin. Obstet. Gynaecol. 1988; 2: 1049-1057
- Cervical cancer: combined modality therapy.Cancer J. 2001; 7: S47-S50
- Weekly cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer: a well-tolerated alternative.Eur. J. Gynaecol. Oncol. 1997; 18: 173-176
- Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results.Gynecol. Oncol. 1997; 67: 61-69
- A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix.J. Clin. Oncol. 1991; 9: 970-977
- Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.J. Clin. Oncol. 1987; 5: 1791-1795
- Phase I/II study of neoadjuvant intraarterial chemotherapy with mitomycin-C, vincristine, and cisplatin in patients with stage IIb bulky cervical carcinoma.Cancer. 1995; 76: 814-823
- Nonparametric estimation from incomplete observations.J. Am. Stat. Assoc. 1958; 58: 457-481
- Micro-computer-assisted univariate survival data analysis using Kaplan–Meier life table estimators.Comput. Methods Programs Biomed. 1988; 27: 223-228
- Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study.J. Clin. Oncol. 2002; 20: 179-188
- Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer.ASCO Annu. Meet. Proc. 2006; 24: 5013
- Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix.Am. J. Clin. Oncol. 2000; 23: 481-486
- Results of a phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri.Gynecol. Oncol. 1988; 31: 256-261
- Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma.Am. J. Clin. Oncol. 1996; 19: 132-135
- A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix.Gynecol. Oncol. 1995; 59: 105-110
- Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri.Gynecol. Oncol. 1990; 38: 486-493
- A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma.Gynecol. Oncol. 1988; 30: 1-6
- Neoadjuvant intraarterial infusion chemotherapy with a combination of mitomycin-C, vincristine, and cisplatin for locally advanced cervical cancer: a preliminary report.Gynecol. Oncol. 1992; 47: 391-394
- Clinical results of transcatheter arterial infusion for uterine cervical cancer.Am. J. Clin. Oncol. 1999; 22: 97-102
- Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix.Gynecol. Oncol. 1989; 35: 130-135
- Close vaginal margins as a prognostic factor after radical hysterectomy.Gynecol. Oncol. 1998; 68: 229-232
- Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix.Gynecol. Oncol. 1989; 33: 34-39
- Histological criteria for the prognosis in patients with operated squamous cell carcinoma of the cervix.Gynecol. Oncol. 1982; 13: 184-194
- Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.N. Engl. J. Med. 1999; 340: 1154-1161
- Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.J. Clin. Oncol. 2005; 23: 4137-4145
- Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.J. Clin. Oncol. 1999; 17: 1339-1348
- Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N. Engl. J. Med. 1999; 340: 1144-1153
- Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.N. Engl. J. Med. 1999; 340: 1137-1143
- Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.Ann. Oncol. 2002; 13: 1212-1219
Received: January 7, 2006
© 2006 Elsevier Inc. Published by Elsevier Inc. All rights reserved.